Table 1.
Clinical studies of allogeneic B-VSTs for opportunistic viral diseases
| Publication | Target | Number of patients | Safety | Response |
|---|---|---|---|---|
| EBV | ||||
| Haque et al, 200224 | EBV-PTLD | 8 | 0 | 3 CR |
| Sun et al, 200225 | EBV-PTLD | 2 | 0 | 1 CR |
| Haque et al, 200726 | EBV-PTLD | 33 | 1 aGVHD | 19 CR |
| Gallot et al, 201427 | Opportunistic EBV-lymphoma | 11 | 1 fever | 3 CR |
| Kazi et al, 201928 | EBV-PTLD | 59 | 2 skin only aGVHD | 23 CR |
| Prockop et al, 202029 | EBV-PTLD | 46 | 1 aGVHD | 21 CR |
| Other viruses | ||||
| Leen et al, 201341 | EBV | 9 | 8 aGVHD | EBV: 2 CR |
| AdV | 23 | AdV: 9 CR | ||
| CMV | 18 | CMV: 7 CR | ||
| Tzannou et al, 201742 | EBV | 2 | 3 de novo aGVHD | EBV: 2 CR |
| AdV | 9 | AdV: 5 CR | ||
| CMV | 19 | 3 aGVHD reactivations | CMV: 9 CR | |
| BKV | 20 | BKV: 6 CR | ||
| HHV-6 | 4 | HHV-6: only partial response | ||
| Withers et al, 201743 | CMV | 28 | 2 de novo aGVHD | CMV: 22 CR |
| EBV | 1 | EBV: 0 CR | ||
| AdV | 1 | AdV: 1 CR | ||
| Tzannou et al, 201952 | CMV | 10 | 0 | CMV: 7 CR |
| Nelson et al, 202044 | BKV | 24 | 1 de novo aGVHD | BK: 77% CR |
| Rubinstein et al, 202145 | AdV | 23 | 1 de novo aGVHD | AdV: 42% CR |
| Olson et al, 202146 | BKV | 59 | 1 de novo aGVHD | BK: 67% CR |
| 1 aGVHD reactivation | ||||
| Jiang et al, 202253 | CMV | 27 | 4 aGVHD | CMV: 25 CR |
| EBV | 3 | EBV: 3 CR | ||
| Pei et al, 202254 | CMV | 31 | 3 aGVHD | CMV: 80.6% CR |
aGVHD, acute graft-versus-host disease.